Approved genetically engineered drugs in Germany

According to vfa research, 352 biopharmaceuticals with 312 active ingredients produced by genetic engineering are currently approved in Germany. Important areas of application include diabetes (insulins), multiple sclerosis and autoimmune diseases such as rheumatoid arthritis and psoriasis (immunomodulators), cancer (monoclonal antibodies), inborn errors of metabolism and coagulation (enzymes, coagulation factors), as well as protective vaccinations (cervical cancer, hepatitis B) and osteoporosis.

Of all the active ingredients approved to date, 12% are produced by genetic engineering; of the new active ingredients introduced each year, the figure is now around 50%.

Some genetically engineered drugs originate from the same production facility, but are approved under different brand names.

All approved biopharmaceuticals are listed below. Approval dates are based on public announcements. The production sites are taken from the public evaluation reports (EPAR) for preparations that have undergone the EU approval procedure in force since 1995. Approval date and field of application (indication) refer to the first approval.